Japan· JP-2290404G2026
デペモキマブ（遺伝子組換え）
A depemokimab product containing デペモキマブ（遺伝子組換え）, registered in Japan by グラクソ・スミスクライン, on the national reimbursement list. The same ATC class is registered in 9 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Depemokimab is registered in 9 of 19 countries.
Countries holding a registration under ATC R03DX12 (depemokimab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 5 of them publish a price we can compare per daily dose
Depemokimab · ATC R03DX12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- デペモキマブ（遺伝子組換え）
- Manufacturer
- グラクソ・スミスクライン
- Country
- Japan (JP)
- ATC code
- R03DX12
- ATC class
- Depemokimab
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Depemokimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesExdensurGlaxoSmithKline LLC
- CzechiaEXDENSURGlaxoSmithKline Trading Services Limited, Dublin
- SpainEXDENSUR 100 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAGlaxosmithkline Trading Services Limited
- FinlandEXDENSURGlaxoSmithKline Trading Services Limited
- United KingdomExdensur 100mg/1ml solution for injection pre-filled pensGlaxoSmithKline UK Ltd
- IrelandEXDENSUR 100 mg solution for injection in pre-filled penGlaxoSmithKline Trading Services Limited
- IcelandEXDENSURGlaxoSmithKline Trading Services Limited
- BelgiumExdensur 100 mgGlaxoSmithKline Trading Services
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Exdensur
- Liechtenstein · Exdensur
- Norway · Exdensur
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9905b22c-e95d-47b4-98a3-b7e9f7078db0 GET /v1/drugs/9905b22c-e95d-47b4-98a3-b7e9f7078db0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ１ｍＬ１キット",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2290404G2026",
"category": "注射薬",
"price_yen": 8503,
"generic_name": "デペモキマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "2290",
"transitional_expiry": "8503"
}See everything about depemokimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.